Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leslie Ber

Adolescent Medicine Houma, LA Medical Doctor

NPI 1386637130 CMS profile 1000834

5642 W Main St, Houma, LA 70360

Open in the dashboard

General payments

$4,374

230 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leslie Ber of Houma, LA is reported in the CMS Open Payments database as having received $4,374 across 230 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Adolescent Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $491 31
2024 General $878 42
2023 General $498 29
2022 General $605 21
2021 General $671 31
2020 General $361 22
2019 General $869 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leslie Ber
  • Adolescent Medicine median
  • Middle half of Adolescent Medicine
  • National median

In program year 2025, general payments to Leslie Ber were reported at $491. Among 914 Adolescent Medicine profiles paid that year, the median was $100 and the middle half received between $40 and $207.

Show as a table
Year Leslie Ber Adolescent Medicine median Middle half National median
2019 $869 $95 $36–$198 $163
2020 $361 $50 $23–$111 $114
2021 $671 $67 $27–$179 $132
2022 $605 $79 $29–$189 $149
2023 $498 $100 $39–$194 $160
2024 $878 $93 $38–$195 $164
2025 $491 $100 $40–$207 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ironshore Pharmaceuticals Inc. $1,009 42 payments
  2. Supernus Pharmaceuticals, Inc. $841 23 payments
  3. Corium, Inc. $722 52 payments
  4. Adlon Therapeutics L.P. $374 23 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $302 16 payments
  6. Collegium Pharmaceutical, Inc. $157 9 payments
  7. Mission Pharmacal Company $134 16 payments
  8. Shire North American Group Inc $126 6 payments
  9. Neos Therapeutics, LP $118 9 payments
  10. Merck Sharp & Dohme Corporation $118 7 payments
  11. Other $474 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,367 229 payments
  2. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Azstarys $722 52 payments
  2. QELBREE Psychology $563 14 payments
  3. JORNAY PM Central Nervous System Stimulant $476 21 payments
  4. ADHANSIA XR $374 23 payments
  5. JORNAY PM Central Nervous Stimulant ADHD $339 17 payments
  6. Qelbree Viloxazine Hydrochloride $278 9 payments
  7. VYVANSE $244 12 payments
  8. Jornay PM 20mg capsules (Bottle of 100) $194 4 payments
  9. Jornay PM Adhd $157 9 payments
  10. Prednisolone 25 $134 16 payments
  11. Other $1,351 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

230 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Adolescent Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record